Detailed Information on Publication Record
2007
Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
GUZI, Timothy, Kamil PARUCH, Michael DWYER, Arshad SIDDIQUI, Panduranga REDDY et. al.Basic information
Original name
Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
Name in Czech
Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
Authors
GUZI, Timothy, Kamil PARUCH, Michael DWYER, Arshad SIDDIQUI, Panduranga REDDY, David BELANGER, Blake HAMANN and Patrick CURRAN
Edition
Number: US 2007/0072882 A1, Publisher: United States Patent and Trademark Office, Place of publication: USA, Owner's name: Schering-Plough, 2007
Other information
Language
English
Type of outcome
Patent
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Organization unit
Faculty of Science
Keywords (in Czech)
pyrazolopyrimidine; cyclin dependent kinase; inhibitor
Keywords in English
pyrazolopyrimidine; cyclin dependent kinase; inhibitor
Změněno: 25/6/2009 15:02, doc. Mgr. Kamil Paruch, Ph.D.
V originále
Title compds. I [R = (un)substituted heteroaryl; R2 = alkyl, alkynyl, CF3, aryl, etc.; R3 = H, halo, alkyl, heteroaryl, etc.; R4 = H, halo or alkyl], and their pharmaceutically acceptable salts, are prepd. and disclosed as inhibitors of cyclin dependent kinases (CDKs). Thus, e.g., II was prepd. by substitution of III (prepn. given) with 3-aminoazetidine. In in vitro kinase activity assays, select compds. of the invention demonstrated IC50 values ranging from 0.05 - 49 (.mu.M). Further disclosed are pharmaceutical compns. contg. one or more of I, methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs using such compds. or pharmaceutical compns.
In Czech
viz Anotace